Cosciens Biopharma Financials
This page shows Cosciens Biopharma (CSCI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Cosciens Biopharma's revenue declined 21.8% year-over-year, from $9.6M to $7.5M. This contraction results in a growth score of 0/100.
Cosciens Biopharma carries a low D/E ratio of 0.50, meaning only $0.50 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.
Cosciens Biopharma's current ratio of 3.18 indicates adequate short-term liquidity, earning a score of 61/100. The company can meet its near-term obligations, though with limited headroom.
While Cosciens Biopharma generated -$8.5M in operating cash flow, capex of $706K consumed most of it, leaving -$9.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Cosciens Biopharma generates a -90.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -116.3% the prior year.
Cosciens Biopharma passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Cosciens Biopharma generates $2.43 in operating cash flow (-$8.5M OCF vs -$3.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Cosciens Biopharma generated $7.5M in revenue in fiscal year 2025. This represents a decrease of 21.8% from the prior year.
Cosciens Biopharma reported -$3.5M in net income in fiscal year 2025. This represents an increase of 77.2% from the prior year.
Cash & Balance Sheet
Cosciens Biopharma generated -$9.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 41.6% from the prior year.
Cosciens Biopharma held $7.3M in cash against $1.9M in long-term debt as of fiscal year 2025.
Cosciens Biopharma had 3M shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.
Margins & Returns
Cosciens Biopharma's net profit margin was -46.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 113.2 percentage points from the prior year.
Cosciens Biopharma's ROE was -90.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25.6 percentage points from the prior year.
Capital Allocation
Cosciens Biopharma invested $706K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.2% from the prior year.
CSCI Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M-46.1% | $2.7M+83.3% | $1.5M-54.8% | $3.3M+77.6% | $1.9M-19.9% | $2.3M+13.6% | $2.1M+23.1% | $1.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $504K+245.2% | -$347K-813.2% | -$38K+98.3% | -$2.2M-616.2% | $426K-77.1% | $1.9M+185800.0% | $1K0.0% | $1K |
| Income Tax | N/A | $1K | N/A | $1.1M+1066.1% | -$112K+76.4% | -$474K-15.0% | -$412K | N/A |
| Net Income | -$1.8M+32.7% | -$2.7M+26.1% | -$3.7M+45.7% | -$6.7M-17.0% | -$5.8M-304.7% | -$1.4M-1.5% | -$1.4M-158.2% | $2.4M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CSCI Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $23.9M-13.4% | $27.6M-11.5% | $31.1M-11.2% | $35.1M-19.9% | $43.8M-12.5% | $50.0M+57.4% | $31.8M+33.9% | $23.7M |
| Current Assets | $13.8M-16.2% | $16.5M-18.9% | $20.4M-15.1% | $24.0M-15.0% | $28.2M-15.0% | $33.2M+6.5% | $31.2M+176.9% | $11.3M |
| Cash & Equivalents | $8.5M-8.7% | $9.3M-32.2% | $13.8M-16.1% | $16.4M-18.0% | $20.0M-28.1% | $27.8M+693.0% | $3.5M-47.5% | $6.7M |
| Inventory | $1.8M-3.4% | $1.8M-25.8% | $2.5M-8.8% | $2.7M-18.6% | $3.3M+8.2% | $3.1M+4673.4% | $64K-98.4% | $4.0M |
| Accounts Receivable | $1.6M-42.3% | $2.8M+49.7% | $1.9M-21.1% | $2.4M+24.6% | $1.9M+52.8% | $1.2M+551.6% | $190K-34.5% | $290K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $18.8M-8.2% | $20.5M-2.6% | $21.0M-4.2% | $21.9M-7.8% | $23.8M-0.3% | $23.8M+26.5% | $18.8M+594.5% | $2.7M |
| Current Liabilities | $4.0M-28.0% | $5.5M-21.6% | $7.1M-2.1% | $7.2M-11.7% | $8.2M-17.5% | $9.9M+88.5% | $5.3M+300.6% | $1.3M |
| Long-Term Debt | $2.0M-4.4% | $2.0M+3.9% | $2.0M-3.2% | $2.0M+68.4% | $1.2M-5.4% | $1.3M+1500.0% | $80K-94.3% | $1.4M |
| Total Equity | $5.1M-28.4% | $7.1M-30.0% | $10.1M-22.9% | $13.2M-34.2% | $20.0M-23.7% | $26.2M+36.7% | $19.2M-8.8% | $21.0M |
| Retained Earnings | -$19.0M-10.6% | -$17.2M-17.6% | -$14.7M-21.0% | -$12.1M-134.8% | -$5.2M-436.5% | $1.5M+100.4% | -$375.3M-8714.9% | $4.4M |
CSCI Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$676K+84.8% | -$4.4M-136.5% | -$1.9M+37.3% | -$3.0M+61.4% | -$7.8M-460.0% | -$1.4M+41.6% | -$2.4M-119.4% | -$1.1M |
| Capital Expenditures | -$4K-108.2% | $49K-92.0% | $615K+99.0% | $309K+135.9% | $131K-16.6% | $157K-72.2% | $564K-3.9% | $587K |
| Free Cash Flow | -$680K+84.9% | -$4.5M-80.2% | -$2.5M+24.6% | -$3.3M+58.2% | -$7.9M-411.6% | -$1.5M+47.5% | -$2.9M-76.1% | -$1.7M |
| Investing Cash Flow | $4K+108.3% | -$48K+92.2% | -$615K-94.6% | -$316K-480.7% | $83K-99.7% | $25.9M+4688.7% | -$564K+5.2% | -$595K |
| Financing Cash Flow | -$85K+20.6% | -$107K+46.5% | -$200K+1.0% | -$202K-7.4% | -$188K-49.2% | -$126K-34.0% | -$94K+43.0% | -$165K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CSCI Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -122.7%-24.4pp | -98.3%+145.4pp | -243.7%-41.1pp | -202.6%+105.0pp | -307.6%-246.7pp | -60.9%+7.3pp | -68.1%-212.1pp | 144.0% |
| Return on Equity | -35.8%+2.3pp | -38.1%-2.0pp | -36.0%+15.1pp | -51.1%-22.4pp | -28.7%-23.3pp | -5.4%+1.9pp | -7.3%-18.7pp | 11.4% |
| Return on Assets | -7.6%+2.2pp | -9.8%+1.9pp | -11.7%+7.4pp | -19.2%-6.0pp | -13.2%-10.3pp | -2.8%+1.6pp | -4.4%-14.5pp | 10.1% |
| Current Ratio | 3.47+0.5 | 2.98+0.1 | 2.88-0.4 | 3.32-0.1 | 3.46+0.1 | 3.35-2.6 | 5.94-2.7 | 8.59 |
| Debt-to-Equity | 0.39+0.1 | 0.29+0.1 | 0.19+0.0 | 0.15+0.1 | 0.06+0.0 | 0.05+0.0 | 0.00-0.1 | 0.07 |
| FCF Margin | -45.9%+117.7pp | -163.5%+2.8pp | -166.3%-66.8pp | -99.6%+323.2pp | -422.8%-356.6pp | -66.1%+77.0pp | -143.1%-43.1pp | -100.1% |
Similar Companies
Frequently Asked Questions
What is Cosciens Biopharma's annual revenue?
Cosciens Biopharma (CSCI) reported $7.5M in total revenue for fiscal year 2025. This represents a -21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cosciens Biopharma's revenue growing?
Cosciens Biopharma (CSCI) revenue declined by 21.8% year-over-year, from $9.6M to $7.5M in fiscal year 2025.
Is Cosciens Biopharma profitable?
No, Cosciens Biopharma (CSCI) reported a net income of -$3.5M in fiscal year 2025, with a net profit margin of -46.5%.
How much debt does Cosciens Biopharma have?
As of fiscal year 2025, Cosciens Biopharma (CSCI) had $7.3M in cash and equivalents against $1.9M in long-term debt.
What is Cosciens Biopharma's net profit margin?
Cosciens Biopharma (CSCI) had a net profit margin of -46.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cosciens Biopharma's return on equity (ROE)?
Cosciens Biopharma (CSCI) has a return on equity of -90.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cosciens Biopharma's free cash flow?
Cosciens Biopharma (CSCI) generated -$9.2M in free cash flow during fiscal year 2025. This represents a 41.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cosciens Biopharma's operating cash flow?
Cosciens Biopharma (CSCI) generated -$8.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cosciens Biopharma's total assets?
Cosciens Biopharma (CSCI) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cosciens Biopharma's capital expenditures?
Cosciens Biopharma (CSCI) invested $706K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cosciens Biopharma's current ratio?
Cosciens Biopharma (CSCI) had a current ratio of 3.18 as of fiscal year 2025, which is generally considered healthy.
What is Cosciens Biopharma's debt-to-equity ratio?
Cosciens Biopharma (CSCI) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cosciens Biopharma's return on assets (ROA)?
Cosciens Biopharma (CSCI) had a return on assets of -16.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cosciens Biopharma's cash runway?
Based on fiscal year 2025 data, Cosciens Biopharma (CSCI) had $7.3M in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cosciens Biopharma's Piotroski F-Score?
Cosciens Biopharma (CSCI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cosciens Biopharma's earnings high quality?
Cosciens Biopharma (CSCI) has an earnings quality ratio of 2.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cosciens Biopharma?
Cosciens Biopharma (CSCI) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.